Peiminine Suppresses RANKL-induced Osteoclastogenesis By Inhibiting The NFATc1 And NF-κB Signaling Pathway

Objective:Osteoclasts(OCs)play an important role in osteoporosis,a disease that is mainly characterized by bone loss.In our research we aimed to identify a novel treatment to regulate osteoclastogenesis and a new approach for treating osteoporosis.Methods:The TRAP staining and bone slice cells culture were performed to determine the inhibitory effect upon the maturity and function of OCs.q PCR and Western-blot were used to test the relative genes and proteins connected with osteoclastogenesis and cells’ function,also,explore the potential target points of peiminine’s inhibitory procedure.Finally,ovariectomized mouse models were established to confirm the therapeutic effect of peiminine in vivo.Results:The results indicated that peiminine effectively suppressed the differentiation of OCs and suppress the differentiation and cytoactive of OCs by decreasing the transcription and expression of specific genes.Additionally,we explored the influence of peiminine on related signaling pathway,and found that NF-κB might be a potential target of peiminine.Moreover,the therapeutic effect of peiminine on preventing bone loss in vivo was confirmed in the ovariectomized mouse models.Conclusion:Peiminine can inhibit the formation and function of OCs via multiple targets.Therefore,it is proved that the peiminie,a natural herb-extracted compound,is a promising novel agent for osteoporosis treatment.